Parkinson disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• SNCA 10
• LRRK2 7
• NRF2 1
• GBA1 13
• NLRP3 1
• PINK1 1
• AKT 0
• PI3K 0
• GLP-1 0
• STING 0
• BDNF 1
• mTOR 0
• SIRT1 0
• TLR4 0
• PPAR 0
• AMPK 1
• TP53 0
• GPX4 0
• MAPK 0
• MAPT 0
• TNF 0
• APOE 1
• HMGB1 0
• JNK 0
• ERK 0
• HSP90 1
• JAK 0
• STAT3 0
• TREM2 0
• HDAC 0
• TDP-43 1
• NMDA 0
• TFEB 0
• HIF-1 1
• IL-1 0
• PARP 0
• CTNNB1 0
• GIP 0
• IL-17 0
• PCSK9 0
• ACE2 0
• AQP4 0
• BCL-2 0
• CSF1R 0
• FTO 0
• PKM2 0
• SGLT2 0
• CD38 0
• COX-2 0
• DPP-4 0
• G6PD 0
• IDO1 0
• PDE4 0
• PTEN 0
• YAP 0
• ALK 0
• APP 0
• ATM 0
• BACE1 0
• C9orf72 0

13 of 13+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Multimodal AI-based Clinical prOgnostic Models for PArkinson's Symptoms progression and Subtyping (mAIcompass)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €435,842· until Nov 2030· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Lithuania· EU contribution €196,976· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Multi-scAle high-order neTwork modelling in the stUdy of human aging: A data-dRiven perspectIve using Topology and geometrY (MATURITY)

  Institut National de Recherche En Informatique Et Automatique· Le Chesnay Cedex, France· EU contribution €226,421· until Jan 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  ENGINEERING NANOPARTICLE-WATER COUPLING; ionic, hypoxic, logic and molecular contrast switches (WATERGATING)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €2,113,066· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Single-vesicle PlAtform for Real-Time detection of membrane-catalyzed Aggregation and transmission (SPARTA)

  Aarhus Universitet· Aarhus C, Denmark· EU contribution €1,500,000· until Nov 2031

  The disease is named only in the funder's project summary, not in the title.

5 of 94 running projects, newest first. Listed amounts together: €184.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

  NCT07348250· Invicro· Updated 27 Jul 2026

  “Study terminated due to site closure.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)

  NCT07216066· Regeneron Pharmaceuticals· Source

• Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution

  NCT06941012· Casa di Cura IGEA· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 19
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 15
• Gene Expression Profiling 76
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 7
• Exome Sequencing 12
• Proteomics 70
• Metabolomics 35
• Mass Spectrometry 12
• Flow Cytometry 4
• Immunohistochemistry 50
• Liquid Biopsy 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 103
• Magnetic Resonance Imaging 369
• Machine Learning 141
• Deep Learning 72
• Cohort Studies 185
• Genome-Wide Association Study 83

• Spatiotemporally resolved single-nucleus transcriptomics reveals cellular and regional vulnerability in the midbrain in Parkinson's disease.

  Signal Transduct Target Ther, Oct 2026

• Gene-based association analysis of depression risk among European ancestry Parkinson's disease patients.

  Hum Genet, Oct 2026

• Exploring metabolic candidates and inflammatory mediation in Parkinson's disease: a pilot integrative metabolomics and Mendelian randomization study.

  PeerJ, Sept 2026

• Interaction Between Cigarette Smoking and PARK16 on Parkinson's Disease.

  Int J Mol Sci, Sept 2026

• Genome-wide cross-trait analysis to compare genetic architecture between Parkinson's disease and kidney-related traits.

  Nat Commun, Sept 2026

• Interrogating DNA methylation associated with Lewy body pathology in a cross brain-region and multi-cohort study.

  Nat Commun, Sept 2026

• Individualized Bayesian Inference Identifies Novel Genetic Variants for Parkinson's Disease.

  Genet Epidemiol, Sept 2026

• Exploring the impacts of type 2 diabetes and metformin use on Parkinson's disease: Mendelian randomization analysis and a national cohort study.

  Neurol Sci, Aug 2026

• Prioritizing Parkinson's disease risk-associated mitochondrial candidate genes via multi-omics integrative analysis.

  Clin Neurol Neurosurg, Aug 2026

• Sex-aware causal inference assessment of the immune system in complex neurodegenerative diseases.

  Brain, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.